Analysing the Serum Levels of Tumour Markers and Primary Tumour Data in Stage III Melanoma Patients in Correlation to the Extent of Lymph Node Metastases—a Prospective Study in 231 Patients

References

• Diepgen T. L., Mahler V. The epidemiology of skin cancer. Br J Dermatol, 2002, 146 Suppl 61: 1–6. Review.
   Google Scholar
• Buzzell R. A., zitelli J. A. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol, 1996, 34: 798–803. Review.
   Google Scholar
• Morton D. L., Thompson J. F., Cochran A. J. et al. MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med, 2006, 355: 1307–1317.
   Google Scholar
• Gershenwald J. E., Thompson W., Mansfield P. F. et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol, 1999, 17: 976–983.
   Google Scholar
• Nowecki घ. I., Rutkowski P., Nasierowska-Guttmejer A., Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol, 2006, 13: 1655–1663. Epub 2006.
   Google Scholar
• Strobbe L. J., Jonk A., Hart A. A., Nieweg O. E., Kroon B. B. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol, 1999, 6: 255–262.
   Google Scholar
• Bishop J. A., Corrie P. G., Evans J. et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg, 2002, 55: 46–54.
   Google Scholar
• Voit C. A., van Akkooi A. C., Schäfer-Hesterberg G. et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol, 2009, 27: 4994–5000. Epub 2009.
   Google Scholar
• van Rijk M. C., Teertstra H. J., Peterse J. L. et al. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol, 2006, 13: 1511–1516. Epub 2006.
   Google Scholar
• Dummer R., Panizzon R., Bloch P. H., Burg G. Task Force Skin Cancer. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology, 2005, 210: 39–44.
   Google Scholar
• Garbe C., Hauschild A., Volkenandt M. et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res, 2007, 17: 393–399.
   Google Scholar
• Garbe C., Schadendorf D., Stolz W et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges, 2008, 6 Suppl 1: S9-S14. English, German.
   Google Scholar
• Deichmann M., Benner A., Bock M., Jäckel A., Uhl K., WaldmannV., Näher H. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol, 1999, 17: 1891–1896.
   Google Scholar
• Deichmann M., Kahle B., Moser K., Wacker J., Wüst K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer, 2004, 91: 699702.
   Google Scholar
• Hornef S., Lux J., Rassner G. [Neuron-specific enolase (NSE)-a suitable tumor marker in malignant melanoma?]. Hautarzt, 1992, 43: 77–80. [Article in German].
   Google Scholar
• Shephard D. A. The 1975 Declaration of Helsinki and Consent. Can Med Assoc J, 1976, 115: 1191–1192.
   Google Scholar
• Mall J. W., Reetz C., Koplin G., Schäfer-Hesterberg G., Voit C., Neuss H. [Surgical technique and postoperative morbity following radical inguinal/iliacal lymph node dissection-a prospective study in 67 patients with malignant melanoma metastatic to the groin]. Zentrbl Chir, 2009, 134: 437–442.
   Google Scholar
• Neuss H., Raue W., Koplin G., Schwenk W., Reetz C., MallJ. W. A prospective randomized trial: the influence of intraoperative application of fibrin glue after radical inguinal/iliacal lymph node dissection on postoperative morbidity. Eur J Surg Oncol, 2009, 35: 884–889. Epub 2008.
   Google Scholar
• Neuss H., Raue W., Koplin G., Schwenk W., Reetz C., Mall J. W. "Intraoperative application of fibrin sealant does not reduce the duration of closed suction drainage following radical axillary lymph node dissection in melanoma patients: a prospective randomized trial in 58 patients". World J Surg, 2008, 32: 14501455.
   Google Scholar
• voit c., Kron M., Schäfer G. et al. ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol, 2006, 13: 1682–1689.
   Google Scholar
• voit c., Kron M., Schoengen A. et al. In vivo and ex vivo ultrasound, fine needle aspiration and molecular biology of Sentinel nodes (SN) in melanoma patients. J Clin Oncol, 2004, 22: 712a.
   Google Scholar
• zentrallabor charité, universitätsmedizin Berlin (central Laboratory, charité university Medicine, Berlin): http://www.charite.de/zlp/routine/referenzdb/(accessed 01-Mar-2010).
   Google Scholar
• Melanom.net: http://www.melanom.net/tnm_melanom.pdf(accessed 01-Mar-2010).
   Google Scholar
• AWMF online: http://leitlinien.net/(accessed 01-Mar-2010).
   Google Scholar
• cascinelli N., Morabito A., Santinami M., MacKie R. M., Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHo Melanoma Programme. Lancet, 1998, 351 (9105): 793–796.
   Google Scholar
• Balch c. M., Soong S. j., Bartolucci A. et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg, 1996, 224: 255–263.
   Google Scholar
• vanAkkooiA. c., voit c. A., verhoef c., EggermontA. M. New developments in sentinel node staging in melanoma: controversies and alternatives. Curr Opin Oncol, 2010, 22: 169–177.
   Google Scholar
• Sim F. H., Taylor W. F., Ivins j. c., Pritchard D. j., Soule E. H. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer, 1978, 41: 948–956.
   Google Scholar
• Veronesi u., Adamus j., Bandiera D. c. et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med, 1977, 297: 627–630.
   Google Scholar
• Hochwald S. N., coit D. G. Role of elective lymph node dissection in melanoma. Semin Surg Oncol, 1998, 14 (4): 276–282.
   Google Scholar
• Henze G., Dummer R., Joller-Jemelka H. I., Böni R., Burg G. Serum S100 — a marker for disease monitoring in metastatic melanoma. Dermatology, 1997, 194: 208–212.
   Google Scholar
• BuerJ., Probst M., FranzkeA. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer, 1997, 75: 1373–1376.
   Google Scholar
• Egberts F., Hitschler W. N., Weichenthal M., Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res, 2009, 19: 31–35.
   Google Scholar
• Abraha H. D., Fuller L. c., Du Vivier A. W., Higgins E. M., Sherwood R. A. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol, 1997, 137: 381–385.
   Google Scholar
• von Schoultz E., Hansson L. o., Djureen E. et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res, 1996, 6: 133–137.
   Google Scholar
• Kruijff S., Bastiaannet E., Kobold A. c., van Ginkel R. j., Suurmeder A. j., Hoekstra H. j. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol, 2009, 16: 3455–3462.
   Google Scholar
• Tarhini A. A., Stuckert j., Lee S., Sander c., Kirkwood j. M. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial EcoG 1694. J Clin Oncol, 2009, 27: 38–44. Epub 2008.
   Google Scholar
• Guo H. B., Stoffel-Wagner B., Bierwirth T., Mezger j., Klingmüller D. clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer, 1995, 31A (6): 924–928. corrected and republished in: Eur J Cancer, 1995, 31A: 18981902.
   Google Scholar
• Acland K., Evans A. V., Abraha H. et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol, 2002, 146: 832835.
   Google Scholar
• Egberts F., Momkvist A., Egberts j. H., Kaehler K. c., Hauschild A. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res, 2010, 30: 1799–1805.
   Google Scholar
• Krähn G., Kaskel P., Sander S. et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res, 2001, 21: 1311–1316.
   Google Scholar
• Deichmann M., Benner A., Waldmann V., Bock M., Jäckel A., Näher H. Interleukin-6 and its surrogate c-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res, 2000, 19: 301–307.
   Google Scholar
• Deichmann M., Polychronidis M., Wacker J., Thome M., Näher H. The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Res, 2001, 11: 577–585.
   Google Scholar
• Deichmann M., Kahle B., Moser K., Wacker J., Wüst K. Diagnosing melanoma patients entering American Joint committee on cancer stage IV, c-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer, 2004, 91: 699–702.
   Google Scholar